Celecoxib/tramadol

{{Short description|Combination drug}}

{{Use American English|date=October 2021}}

{{Use dmy dates|date=October 2021}}

{{Infobox drug

| drug_name =

| type = combo

| image =

| width =

| alt =

| image2 =

| width2 =

| alt2 =

| caption =

| component1 = Celecoxib

| class1 = Nonsteroidal anti-inflammatory drug (NSAID)

| component2 = Tramadol hydrochloride

| class2 = Opioid agonist

| tradename = Seglentis

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID = Celecoxib_and_tramadol

| licence_US =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| dependency_liability =

| addiction_liability =

| routes_of_administration = By mouth

| ATCvet =

| ATC_prefix = N02

| ATC_suffix = AJ16

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Schedule IV

| legal_US_comment = {{cite web | title=Seglentis- celecoxib and tramadol hydrochloride tablet | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf2c8436-a9f3-473c-e053-2a95a90a1123 | access-date=8 January 2022}}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number_Ref =

| CAS_number =

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank_Ref =

| DrugBank =

| ChemSpiderID_Ref =

| ChemSpiderID =

| UNII_Ref =

| UNII =

| KEGG_Ref =

| KEGG = D12491

| ChEBI_Ref =

| ChEBI =

| ChEMBL_Ref =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = E-58425

}}

Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.

Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.{{cite web | title=Seglentis: FDA-Approved Drugs | website=U.S. Food and Drug Administration | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213426 | access-date=18 October 2021}}{{cite press release | title=Esteve Announces FDA Approval Of A Novel Co-Crystal Form Of Celecoxib And Tramadol For The Management Of Acute Pain | website=Esteve | date=15 October 2021 | url=https://www.esteve.com/global/news/esteve-announces-fda-approval-of-a-novel-co-crystal-form-of-celecoxib-and-tramadol-for-the-management-of-acute-pain | access-date=18 October 2021}}